Private Management Group Inc. Lowers Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Private Management Group Inc. cut its Johnson & Johnson stake by 24.9% in Q3, selling 44,655 shares and ending the period with 134,750 shares valued at about $24.99 million.
• Company insiders sold a total of 30,142 JNJ shares worth approximately $7.36 million in the last three months, including EVP Timothy Schmid and EVP Vanessa Broadhurst, who materially reduced their holdings.
• Positive catalysts and analyst support are building—FDA approval for the TECNIS PureSee IOL and promising Phase 1 Erda‑iDRS data, while banks like BofA and Citigroup have raised price targets (BofA $253, Citi $274), contributing to a consensus "Moderate Buy" and a $235.91 average target.

Private Management Group Inc. lessened its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 24.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 134,750 shares of the company's stock after selling 44,655 shares during the quarter. Private Management Group Inc.'s holdings in Johnson & Johnson were worth $24,985,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company's stock valued at $36,209,060,000 after acquiring an additional 3,085,180 shares in the last quarter. Norges Bank acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $4,877,174,000. Bank of New York Mellon Corp boosted its stake in shares of Johnson & Johnson by 3.5% in the third quarter. Bank of New York Mellon Corp now owns 24,637,649 shares of the company's stock valued at $4,568,313,000 after purchasing an additional 835,146 shares during the period. Legal & General Group Plc boosted its stake in shares of Johnson & Johnson by 2.8% in the third quarter. Legal & General Group Plc now owns 19,450,064 shares of the company's stock valued at $3,606,431,000 after purchasing an additional 532,790 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Johnson & Johnson by 0.3% in the second quarter. Charles Schwab Investment Management Inc. now owns 18,951,337 shares of the company's stock valued at $2,894,979,000 after purchasing an additional 52,074 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approves the TECNIS PureSee intraocular lens, adding a new, differentiated cataract/presbyopia product to J&J’s surgical vision portfolio — could support revenue and aftermarket growth in the medtech segment. FDA Approval Of TECNIS PureSee IOL Adds New Lens For J&J Investors
• Positive Sentiment: Promising Phase 1 Erda‑iDRS (erdafitinib) results in intermediate‑risk NMIBC: 89% complete response rate and durable responses up to 18 months with tolerable safety — bolsters oncology pipeline optionality if later‑stage data confirm benefit. Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer
• Positive Sentiment: BofA raised its price target (to $253) and lifted revenue expectations citing pipeline growth — supportive analyst attention that can underpin sentiment even with a Neutral rating. BofA Raises Johnson & Johnson (JNJ) Price Target on Pipeline Growth
• Positive Sentiment: Citigroup analyst expects JNJ shares to rise — additional buy-side commentary can amplify positive flows if confirmed with upgrades or higher targets. Johnson & Johnson NYSE: JNJ Stock Price Expected to Rise, Citigroup Analyst Says
• Neutral Sentiment: Dividend and “Dividend King” coverage reminds investors of JNJ’s income profile — supportive for long‑term holders but unlikely to drive short‑term price swings. Johnson & Johnson (JNJ) Could Be a Great Choice
• Neutral Sentiment: Barclays reaffirmed its Hold rating — steady analyst stance that tempers upside momentum from positive news. Barclays Reaffirms Their Hold Rating on Johnson & Johnson (JNJ)
• Neutral Sentiment: Industry pieces on BCG shortages and competitor ImmunityBio note market dynamics in NMIBC — useful context for future demand shifts but not an immediate JNJ catalyst. IBRX and the BCG Shortage: A 2026 Catalyst Investors Are Tracking
• Neutral Sentiment: Analyst / valuation updates show modest shifts in fair value assumptions tied to individual drugs (Tremfya, Tecvayli, Inlexzo, Darzalex) — indicates ongoing re‑rating risk/reward as pipeline readouts arrive. How The Johnson & Johnson (JNJ) Narrative Is Shifting With Pipeline Rethinks And New Valuation Targets
• Negative Sentiment: Preliminary approval of a $65M eve‑of‑trial settlement in an antitrust suit tied to Actelion’s Tracleer — modest direct financial hit but reputational/legal overhang for the pharma legacy business. Eve-of-Trial $65M Settlement Preliminarily Approved in Novel Antitrust Class Action Against J&J Subsidiary Actelion Pharmaceuticals

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total value of $324,762.52. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,251,310.02. This represents a 4.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the firm's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 30,142 shares of company stock worth $7,360,528 in the last three months. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $241.71 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The company has a fifty day simple moving average of $231.91 and a 200-day simple moving average of $206.23. The stock has a market cap of $582.50 billion, a P/E ratio of 21.87, a price-to-earnings-growth ratio of 2.39 and a beta of 0.34. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Saturday, January 31st. The company reported $2.46 EPS for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion for the quarter. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were issued a $1.30 dividend. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.2%. Johnson & Johnson's dividend payout ratio is presently 47.06%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research reports. Sanford C. Bernstein increased their target price on shares of Johnson & Johnson from $208.00 to $225.00 and gave the stock a "market perform" rating in a report on Friday, January 23rd. Citigroup boosted their price target on shares of Johnson & Johnson from $250.00 to $274.00 and gave the stock a "buy" rating in a research note on Wednesday. Rothschild & Co Redburn upped their price objective on Johnson & Johnson from $180.00 to $210.00 and gave the stock a "neutral" rating in a research report on Thursday, February 19th. HSBC lifted their target price on Johnson & Johnson from $240.00 to $265.00 and gave the company a "buy" rating in a report on Friday, January 30th. Finally, Barclays boosted their target price on Johnson & Johnson from $197.00 to $217.00 and gave the stock an "equal weight" rating in a research note on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $235.91.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.